FDA Says It Will Find And Fill Gaps In Response To Independent Assessment
This article was originally published in The Gray Sheet
Executive Summary
The agency issued a plan of action in response to four top-line recommendations from Booz Allen Hamilton’s preliminary report that was issued in December.
You may also be interested in...
Big Uptick In Withdrawn 510(k)s Highlighted In Booz Allen Assessment
The consulting group issued its final assessment of FDA’s device review program following a year-long examination; it includes 11 recommendations for improvements. Among the new directives that were not included in Booz Allen’s interim report in December: FDA should perform a large study of withdrawn device submissions to figure out how to limit the growing practice.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.